Summary
Environmental enteric dysfunction (EED) is a subclinical condition of the gut characterized by changes in morphology and function with underlying chronic inflammatory responses. This study characterized composition and diversity of the gut microbiota in rural Malawian children with and without signs of EED. Fecal samples were collected from children aged 1-59 months. Neopterin, myeloperoxidase and alpha-1 antitrypsin concentrations were quantified by ELISA and combined to form a composite EED score using principal component analysis. DNA was extracted from fecal samples and V4-16S rRNA sequencing was used to characterize the gut microbiota. The concentrations of all three biomarkers decreased with increasing age, which is consistent with other studies of children living in similar low-income settings. Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria were the dominant phyla while Faecalibacterium and Bifidobacterium were the most prevalent genera. Increased alpha diversity was associated with a reduction in neopterin concentration. Microbiota composition was associated with the composite EED score. Increased abundance of Succinivibrio was associated with reduced composite EED scores.
Highlights
In Malawian children, fecal concentrations of myeloperoxidase, alpha-1 antitrypsin and neopterin decreased with age
A marginal negative association was found between alpha diversity of the gut microbiota and fecal neopterin concentration
A higher abundance of Succinivibrio was found in children with lower concentrations of biomarker of environmental enteric dysfunction
Fatty acid biosynthesis, tetrapyrrole biosynthesis and pyrimidine nucleotide degradation pathways were associated with environmental enteric dysfunction biomarker score
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.preprints.org/manuscript/202010.0138/v1
Funding Statement
Funding for this work was provided by the Bill and Melinda Gates Foundation, under grant numbers OPP1066930 and OP1032340
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The London School of Hygiene and Tropical Medicine Ethics Committee (UK) and the College of Medicine Research Ethics Committee (Malawi)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets generated from the present study are available from the corresponding author on reasonable request. The V4 16S rRNA sequence data for this study have been deposited in the European Nucleotide Archive (ENA) at EMBL-EBI under accession number PRJEB41238
